Article
Oncology
Andrew J. Armstrong, Arun A. Azad, Taro Iguchi, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Antonio Alcaraz, Boris Alekseev, Neal D. Shore, Francisco Gomez-Veiga, Brad Rosbrook, Fabian Zohren, Shunsuke Yamada, Gabriel P. Haas, Arnulf Stenzl
Summary: Clinical Trial Updates provide an opportunity to disseminate additional results from studies that have already reported their primary endpoint. This study demonstrates that enzalutamide plus androgen deprivation therapy significantly prolongs survival in patients with metastatic hormone-sensitive prostate cancer, and continues to improve other secondary endpoints.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Volkan Sabur, Ibrahim Untan, Atila Tatlisen
Summary: The study demonstrated that PSADT, PSAV, and nadir PSA are independent prognostic markers for survival in patients with HRPCa, helping clinicians predict survival in these patients.
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN
(2021)
Article
Oncology
Aurore Carrot, Reza-Thierry Elaidi, Olivier Colomban, Denis Maillet, Michel Tod, Benoit You, Stephane Oudard
Summary: This study analyzed a phase III trial dataset in metastatic prostate cancer patients, demonstrating the significant prognostic value of modeled PSA kinetics parameters assessed using mathematical modeling. The results suggest that these parameters could serve as early prognostic/predictive factors in patients undergoing systemic treatments.
Article
Oncology
Amir Goldkorn, Catherine Tangen, Melissa Plets, Gareth J. Morrison, Alexander Cunha, Tong Xu, Jacek K. Pinski, Sue A. Ingles, Timothy Triche, Andrea L. Harzstark, Manish Kohli, Gary R. MacVicar, Daniel A. Vaena, Anthony W. Crispino, David J. McConkey, Primo N. Lara, Maha H. A. Hussain, David I. Quinn, Nicholas J. Vogelzang, Ian Murchie Thompson, Neeraj Agarwal
Summary: The CellSearch CTC count can effectively predict the PSA levels within 7 months and progression-free survival within 2 years in mCSPC patients. Patients with undetectable CTCs have a higher chance of achieving favorable treatment outcomes.
CLINICAL CANCER RESEARCH
(2021)
Article
Medicine, General & Internal
Cheng-Yu Huang, Chung-Hsin Chen
Summary: The study aimed to investigate the clinical presentation and survival outcomes of patients with both a high PSA value and non-metastatic prostate cancer. The results showed that patients with non-metastatic prostate cancer and high PSA levels obtained survival benefits from local prostate-definitive treatments.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2022)
Article
Oncology
Lorenzo Bianchi, Francesco Ceci, Francesco Costa, Eleonora Balestrazzi, Matteo Droghetti, Pietro Piazza, Alessandro Pissavini, Riccardo Mei, Andrea Farolfi, Paolo Castellucci, Stefano Puliatti, Alessandro Larcher, Giorgio Gandaglia, Daniele Robesti, Alexandre Mottrie, Alberto Briganti, Alessio Giuseppe Morganti, Stefano Fanti, Francesco Montorsi, Riccardo Schiavina, Eugenio Brunocilla
Summary: This study aims to evaluate the oncologic outcomes of patients with recurrent prostate cancer who received PSMA-PET. The results of PSMA-PET had no significant impact on the oncologic outcomes of recurrent prostate cancer patients who never received previous salvage therapies. However, for recurrent prostate cancer patients who had previous salvage therapies, positive PSMA-PET results were associated with worse oncologic outcomes.
Article
Oncology
Chun Wang, Zhenchao Zhang, Weelic Chong, Rui Luo, Ronald E. Myers, Jian Gu, Jianqing Lin, Qiang Wei, Bingshan Li, Timothy R. Rebbeck, Grace Lu-Yao, William K. Kelly, Hushan Yang
Summary: This study investigated the associations of CTCs and CTC-clusters with mCRPC prognosis using longitudinal samples, finding that CTC counts were associated with mCRPC outcomes, and the presence of CTC-clusters alone had prognostic value, improving CTC-based prognostic stratification. The findings suggest the potential of combining CTC and CTC-clusters as non-invasive means to monitor progression and predict survival in mCRPC.
Article
Oncology
Jeremiah Wala, Paul Nguyen, Mark Pomerantz
Summary: The Oncology Grand Rounds series aims to provide clinical context for original reports published in the Journal of Clinical Oncology. This article discusses the use of androgen deprivation therapy (ADT) and the recent advancements in treatment for metastatic hormone-sensitive prostate cancer (mHSPC). The addition of second-generation oral androgen-receptor pathway inhibitors (ARPIs) or docetaxel to ADT has shown improved outcomes, and studies are also examining the role of radiotherapy (RT) in mHSPC.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Lara Franziska Stolzenbach, Giuseppe Rosiello, Marina Deuker, Thomas Martin, Sophie Knipper, Zhe Tian, Alberto Briganti, Kevin C. Zorn, Fred Saad, Felix K. H. Chun, Markus Graefen, Pierre I. Karakiewicz
Summary: The study indicates that metastatic prostate cancer patients with intermediate life expectancy and low PSA levels may benefit from external beam radiation therapy (EBRT) in reducing overall mortality, especially in M1a and M1b sub-stages. It is suggested to consider EBRT treatment more in these patients, but study limitations should be taken into account until clinical trials confirm the potential benefits.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
Article
Urology & Nephrology
Sarah Buelens, Filip Poelaert, Tom Claeys, Elise De Bleser, Bert Dhondt, Wesley Verla, Piet Ost, Bernard Rappe, Bart De Troyer, Caroline Verbaeys, Bart Kimpe, Ignace Billiet, Hendrik Plancke, Karen Fransis, Patrick Willemen, Filip Ameye, Karel Decaestecker, Nicolaas Lumen
Summary: The study aimed to investigate the role of cytoreductive radical prostatectomy in patients with newly diagnosed metastatic prostate cancer. The results showed longer castration resistant cancer-free survival and higher local event-free survival in the surgery group. However, there was no significant difference between treatment groups in the multivariable analysis.
Article
Oncology
Qi Miao, Zhihao Wei, Chenchen Liu, Yuzhong Ye, Gong Cheng, Zhengshuai Song, Kailei Chen, Yunxuan Zhang, Jiawei Chen, Changjie Yue, Hailong Ruan, Xiaoping Zhang
Summary: Radical prostatectomy (RP) shows significant advantages over radiation therapy (RT) in improving overall survival (OS) and cancer-specific survival (CSS) for metastatic prostate cancer (mPCa).
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Simona Ferraro, Marco Bussetti, Niccolo Bassani, Roberta Simona Rossi, Giacomo Piero Incarbone, Filippo Bianchi, Marco Maggioni, Letterio Runza, Ferruccio Ceriotti, Mauro Panteghini
Summary: This study defined PSA thresholds using a well calibrated risk prediction model to personalize the diagnostic workup for advanced prostate cancer. PSA concentrations can exclude or suggest biopsy referral, but may not provide a valid estimate for cancer risk in patients with glandular inflammation.
Article
Oncology
Michael J. Grayling, Martina McMenamin, Robert Chandler, Rakesh Heer, James M. S. Wason
Summary: The augmented PSA response analysis method can improve the efficiency of prostate cancer trials in clinical practice without the need for additional data collection. This method improves the precision of estimation to a degree that is equivalent to a substantial increase in sample size. The importance of this study lies in the fact that prostate cancer trials using PSA response as a primary endpoint can be conducted with fewer participants, leading to faster completion and reduced costs.
Article
Pharmacology & Pharmacy
Nityam Rathi, Taylor Ryan McFarland, Roberto Nussenzveig, Neeraj Agarwal, Umang Swami
Summary: Immunotherapies have shown success in treating multiple cancer types, but have faced challenges in prostate cancer. The immune evasion in prostate cancer is attributed to intrinsic tumor factors, immunosuppressive tumor microenvironment, and host factors. Researchers are exploring ways to transform prostate cancer from a 'cold' tumor to a 'hot' tumor through various approaches, including immune checkpoint inhibitors and other upcoming immunotherapies.
Article
Urology & Nephrology
David Lorente, Casilda Llacer, Rebeca Lozano, Guillermo de Velasco, Nuria Romero-Laorden, Miguel Rodrigo, Angel Sanchez-Iglesias, Carlos di Capua, Elena Castro, Carlos Ferrer, Alfredo Sanchez-Hernandez, David Olmos
Summary: This study validated the prognostic value of the Armstrong risk model in patients treated with first-line androgen receptor signaling inhibitors, showing that low-risk patients received the greatest benefit. Further research is needed to establish the role of Armstrong risk groups for treatment selection in mCRPC patients.
Article
Public, Environmental & Occupational Health
Wahyu Wulaningsih, Karl Michaelsson, Hans Garmo, Niklas Hammar, Ingmar Jungner, Goran Walldius, Mats Lambe, Lars Holmberg, Mieke Van Hemelrijck
Article
Oncology
David Robinson, Hans Garmo, Bertil Lindahl, Mieke Van Hemelrijck, Jan Adolfsson, Ola Bratt, Lars Holmberg, Par Stattin
INTERNATIONAL JOURNAL OF CANCER
(2012)
Article
Multidisciplinary Sciences
Mieke Van Hemelrijck, Hans Garmo, Karl Michaelsson, Andreas Thorstenson, Olof Akre, Par Stattin, Lars Holmberg, Jan Adolfsson
Article
Medicine, General & Internal
Lars Berglund, Christian Berne, Kurt Svardsudd, Hans Garmo, Hakan Melhus, Bjorn Zethelius
UPSALA JOURNAL OF MEDICAL SCIENCES
(2012)
Article
Oncology
Frederik Birkebaek Thomsen, Cecilia Bosco, Hans Garmo, Jan Adolfsson, Niklas Hammar, Par Stattin, Mieke Van Hemelrijck
Article
Oncology
Marcus Westerberg, Ingela Franck Lissbrant, Jan Erik Damber, David Robinson, Hans Garmo, Par Stattin
Article
Oncology
Kerri Beckmann, Hans Garmo, Per Nilsson, Ingela Franck Lissbrant, Anders Widmark, Par Stattin
Article
Urology & Nephrology
Gincy George, Hans Garmo, Sarah Rudman, Lars Holmberg, David Robinson, Par Stattin, Jan Adolfsson, Mieke Van Hemelrijck
SCANDINAVIAN JOURNAL OF UROLOGY
(2020)
Article
Urology & Nephrology
Magdalena Lycken, Linda Drevin, Hans Garmo, Anders Larsson, Ove Andren, Lars Holmberg, Anna Bill-Axelson
SCANDINAVIAN JOURNAL OF UROLOGY
(2020)
Article
Urology & Nephrology
Anna Pia Enblad, Oskar Bergengren, Ove Andren, Anders Larsson, Katja Fall, Eva Johansson, Hans Garmo, Anna Bill-Axelson
SCANDINAVIAN JOURNAL OF UROLOGY
(2020)
Article
Oncology
Gincy George, Hanna Vikman, Rolf Gedeborg, Ingela Franck Lissbrant, Hans Garmo, Johan Styrke, Mieke Van Hemelrijck, Par Stattin
Summary: Men with castration resistant prostate cancer (CRPC) on GnRH plus androgen receptor targeted (ART) drugs such as abiraterone or enzalutamide have an increased risk of cardiovascular disease (CVD), especially those with a recent history of CVD. It is recommended to closely monitor the cardiovascular health of these patients.
Article
Urology & Nephrology
Karl-Johan Lundstrom, Hans Garmo, Rolf Gedeborg, Par Stattin, Johan Styrke
Summary: This study examined the risk of aortic aneurysm after short-term ciprofloxacin as prophylaxis for prostate biopsy, and found that short-term ciprofloxacin was not associated with an increased risk of aortic aneurysm. However, an increased risk of aortic aneurysm was observed in men diagnosed with high-risk prostate cancer, likely due to detection bias caused by more commonly performed imaging in these men.
SCANDINAVIAN JOURNAL OF UROLOGY
(2021)
Article
Oncology
Giuseppe Fallara, Charlotte Alverbratt, Hans Garmo, Hanna Vikman, Marie Hjelm Eriksson, Ingela Franck Lissbrant, Par Stattin
Summary: The study analyzed data from the National Prostate Cancer Register of Sweden and found that in clinical practice, time on treatment with androgen receptor-targeted drugs in men with metastatic castration-resistant prostate cancer who had not received chemotherapy was shorter than in published randomized controlled trials, possibly due to factors such as older age, poorer performance status, and more comorbidities.
Letter
Oncology
Rolf Gedeborg, Hans Garmo, Camilla Thellenberg-Karlsson, Giuseppe Fallara, Johan Styrke, Ingela Franck Lissbrant, Par Stattin
Article
Urology & Nephrology
Tiago M. Bonde, Marcus Westerberg, Markus Aly, Martin Eklund, Jan Adolfsson, Anna Bill-Axelson, Hans Garmo, Par Stattin, David Robinson
Summary: The objective of this study was to predict CRPC and Pca death using clinical variables and PSA levels. The results showed that post-GnRH PSA and ISUP grade were associated with the risk of CRPC and Pca death.
SCANDINAVIAN JOURNAL OF UROLOGY
(2022)